The most common cancer among males in eastern and western Europe is prostate cancer, which accounts for roughly 190,000 new cases yearly or 15% of all cancers in men. The condition's origins are mostly unclear, while hormonal variables and nutritional habits may indirectly contribute; several genes that may be connected to hereditary prostate cancer (HPC) have been found. Increased serum prostate-specific antigen (PSA) levels and/or questionable digital rectal examination (DRE) results can point to prostate cancer. Nonetheless, a definite prostate biopsy was required for a conclusive confirmation. The best course of action is determined by the patient's condition, overall health, disease severity, and first PSA stage. Radical prostatectomy and radiation treatment (with or without hormone deprivation therapy) might be the best options in the cases mentioned of local disease . In patient with well or poorly differentiated tumors and a mortality rate of fewer than 10 years, the observant delay is recommended as the preferred approach. In 80–85% of instances of progressive disease, hormone deprivation therapy is the preferred treatment when paired with radiation for advanced or metastatic or bulky illness. It is helpful but not therapeutic in these cases. Although Docetaxel has recently been shown to increase life expectancy and overall survival (2 to 2.5 months), individuals who acquire hormone-refractory prostate cancer illness (HRPC) must be examined for treatment.